Red Crane Wealth Management LLC Takes $515,000 Position in Amgen Inc. (NASDAQ:AMGN)

Red Crane Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,975 shares of the medical research company's stock, valued at approximately $515,000.

• MarketBeat Week in Review – 12/2 - 12/6

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Talbot Financial LLC boosted its stake in shares of Amgen by 5.6% during the 4th quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company's stock worth $11,153,000 after acquiring an additional 2,274 shares during the period. Swiss National Bank boosted its position in Amgen by 0.3% during the third quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company's stock worth $513,033,000 after purchasing an additional 5,500 shares during the period. Asset Advisors Investment Management LLC increased its holdings in shares of Amgen by 9.0% in the third quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company's stock valued at $11,578,000 after purchasing an additional 2,954 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Amgen by 6.0% in the third quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company's stock valued at $204,659,000 after purchasing an additional 35,785 shares during the period. Finally, Ascent Wealth Partners LLC lifted its stake in shares of Amgen by 0.7% during the 4th quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after buying an additional 64 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

AMGN has been the topic of a number of research reports. Jefferies Financial Group reiterated a "buy" rating and issued a $380.00 price target on shares of Amgen in a research note on Tuesday, November 12th. Wolfe Research started coverage on Amgen in a research report on Friday, November 15th. They issued a "peer perform" rating on the stock. Redburn Partners dropped their price target on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Finally, UBS Group reissued a "hold" rating on shares of Amgen in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Amgen currently has an average rating of "Hold" and an average price target of $314.09.

• Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?

Read Our Latest Analysis on Amgen

Insider Transactions at Amgen

In other Amgen news, EVP David M. Reese sold 8,711 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the sale, the executive vice president now directly owns 62,147 shares of the company's stock, valued at $18,222,743.34. The trade was a 12.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,341 shares of company stock worth $20,644,335. Corporate insiders own 0.69% of the company's stock.

Amgen Stock Performance

• 2 Generic Drug Stocks Ready to Surge in 2025

NASDAQ:AMGN opened at $315.63 on Wednesday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The stock's 50-day simple moving average is $278.13 and its 200 day simple moving average is $300.16. The firm has a market capitalization of $169.56 billion, a PE ratio of 41.81, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Amgen's previous quarterly dividend of $2.25. Amgen's payout ratio is presently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

See Also

• Five stocks we like better than Amgen
• Do ETFs Pay Dividends? What You Need to Know
• Tempus AI Is a Buy, If You Can Handle the Volatility
• Stock Sentiment Analysis: How it Works
• Massive Buybacks: 3 Stocks Returning Big Cash to Shareholders
• 3 Tickers Leading a Meme Stock Revival
• Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Amgen Right Now?

Before you consider Amgen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.

While Amgen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here